Smith Jennifer S, Green Jane, Berrington de Gonzalez Amy, Appleby Paul, Peto Julian, Plummer Martyn, Franceschi Silvia, Beral Valerie
International Agency for Research on Cancer, Lyon, France.
Lancet. 2003 Apr 5;361(9364):1159-67. doi: 10.1016/s0140-6736(03)12949-2.
Human papillomavirus (HPV) is believed to be the most important cause of cervical cancer. Recent studies suggest that long duration use of oral contraceptives increases the risk of cervical cancer in HPV positive women.
Results from published studies were combined to examine the relationship between invasive and in situ cervical cancer and duration and recency of use of hormonal contraceptives, with particular attention to HPV infection.
28 eligible studies were identified, together including 12531 women with cervical cancer. Compared with never users of oral contraceptives, the relative risks of cervical cancer increased with increasing duration of use: for durations of approximately less than 5 years, 5-9 years, and 10 or more years, respectively, the summary relative risks were 1.1 (95% CI 1.1-1.2), 1.6 (1.4-1.7), and 2.2 (1.9-2.4) for all women; and 0.9 (0.7-1.2), 1.3 (1.0-1.9), and 2.5 (1.6-3.9) for HPV positive women. The results were broadly similar for invasive and in situ cervical cancers, for squamous cell and adenocarcinoma, and in studies that adjusted for HPV status, number of sexual partners, cervical screening, smoking, or use of barrier contraceptives. The limited available data suggest that the relative risk of cervical cancer may decrease after use of oral contraceptives ceases. However, study designs varied and there was some heterogeneity between study results.
Although long duration use of hormonal contraceptives is associated with an increased risk of cervical cancer, the public health implications of these findings depend largely on the extent to which the observed associations remain long after use of hormonal contraceptives has ceased, and this cannot be evaluated properly from published data.
人乳头瘤病毒(HPV)被认为是宫颈癌的最重要病因。近期研究表明,长期使用口服避孕药会增加HPV阳性女性患宫颈癌的风险。
综合已发表研究的结果,以检验浸润性和原位宫颈癌与激素避孕药使用时长及近期使用情况之间的关系,尤其关注HPV感染情况。
共确定了28项符合条件的研究,总计纳入12531名宫颈癌女性患者。与从未使用过口服避孕药的女性相比,患宫颈癌的相对风险随使用时长增加而上升:对于使用时长分别约小于5年、5 - 9年以及10年及以上的情况,所有女性的汇总相对风险分别为1.1(95%置信区间1.1 - 1.2)、1.6(1.4 - 1.7)和2.2(1.9 - 2.4);HPV阳性女性的相应汇总相对风险分别为0.9(0.7 - 1.2)、1.3(1.0 - 1.9)和2.5(1.6 - 3.9)。浸润性和原位宫颈癌、鳞状细胞癌和腺癌的结果大致相似,在针对HPV状态、性伴侣数量、宫颈筛查、吸烟或屏障避孕法使用情况进行调整的研究中也是如此。有限的现有数据表明,停用口服避孕药后患宫颈癌的相对风险可能会降低。然而,研究设计各不相同,研究结果之间存在一定异质性。
尽管长期使用激素避孕药与患宫颈癌风险增加有关,但这些发现对公共卫生的影响很大程度上取决于在停用激素避孕药后观察到的关联持续的时间,而这无法从已发表的数据中得到恰当评估。